The earnings call presented a strong performance with record revenue and improved gross margins, alongside successful debt refinancing and positive clinical trial data. However, challenges included increased operating expenses, a higher net loss, and the NAUTILUS trial not meeting its primary effectiveness endpoint.

Company Guidance -

Q3 2025

During NeuroPace, Inc.'s Second Quarter 2025 earnings call, the company provided updated financial guidance, reflecting a strong performance. NeuroPace reported record revenue of $23.5 million for the quarter, marking a 22% increase from the previous year. The company adjusted its full-year revenue guidance to a range of $94 million to $98 million, up from the prior range of $93 million to $97 million, and raised its gross margin guidance to between 75% and 76%. Operating expenses, excluding one-time items, grew by 13%, staying below the revenue growth rate. The RNS System revenue grew 16% during the quarter, contributing to this performance. NeuroPace also highlighted successful refinancing of its debt, providing financial flexibility, and discussed ongoing clinical development programs, including its NAUTILUS trial and Project CARE. The company expressed confidence in its growth trajectory, bolstered by clinical data, strategic partnerships, and planned innovations.

Record Revenue Growth

NeuroPace reported a record revenue of $23.5 million for Q2 2025, representing a 22% growth compared to $19.3 million in the previous year.

Strong Gross Margin Performance

The company achieved a total gross margin above 77% and an RNS gross margin above 80%. The gross margin guidance for the full year was raised to a range of 75% to 76%.

Successful Debt Refinancing

NeuroPace completed a refinancing of its existing debt, securing more favorable terms and enhancing financial flexibility.

Positive Clinical Trial Results

The Post-Approval Study showed a 100% median percent seizure reduction at 24 and 36 months post-implant for patients with generalized tonic-clonic seizures.

Encouraging NAUTILUS Trial Data

NAUTILUS trial data showed highly statistically significant and clinically meaningful reductions in seizure frequency, with a median seizure reduction better than 80% at 18 and 24 months.

NeuroPace (NPCE) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

NPCE Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 11, 2025	2025 (Q3)	-0.20 / -	-0.19	―	―	―
Aug 12, 2025	2025 (Q2)	-0.22 / -0.26	-0.26	0.00% (0.00)	―
May 13, 2025	2025 (Q1)	-0.24 / -0.21	-0.32	34.38% (+0.11)
Mar 04, 2025	2024 (Q4)	-0.22 / -0.18	-0.23	21.74% (+0.05)
Nov 12, 2024	2024 (Q3)	-0.27 / -0.19	-0.28	32.14% (+0.09)
Aug 13, 2024	2024 (Q2)	-0.30 / -0.26	-0.36	27.78% (+0.10)
May 08, 2024	2024 (Q1)	-0.32 / -0.32	-0.41	21.95% (+0.09)
Mar 05, 2024	2023 (Q4)	-0.32 / -0.23	-0.45	48.89% (+0.22)	―
Nov 06, 2023	2023 (Q3)	-0.40 / -0.28	-0.48	41.67% (+0.20)	―
Aug 08, 2023	2023 (Q2)	-0.47 / -0.36	-0.52	30.77% (+0.16)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

NPCE Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 12, 2025	$9.13	$9.32	+2.08%
May 13, 2025	$12.95	$15.60	+20.46%
Mar 04, 2025	$11.92	$11.63	-2.43%
Nov 12, 2024	$7.14	$9.15	+28.15%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Neuropace, Inc. (NPCE) report earnings?

Neuropace, Inc. (NPCE) is schdueled to report earning on Nov 11, 2025, After Close (Confirmed).

What is Neuropace, Inc. (NPCE) earnings time?

Neuropace, Inc. (NPCE) earnings time is at Nov 11, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is NPCE EPS forecast?

NPCE EPS forecast for the fiscal quarter 2025 (Q3) is -0.2.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing